OrbiMed’s AC Immune ACIU Stock Holding History

OrbiMed’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,440,000	Closed	-$13.6M	–	125
2018 Q4	$13.6M	Hold	1,440,000	–	–	0.25%	79
2018 Q3	$11.5M	Buy	+1,440,000	New	+$14.5M	0.14%	108

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

OrbiMed's ACIU Position: Q1 2019 in Review

OrbiMed sold out of AC Immune (ACIU) in Q1 2019, closing a stake of 1,440,000 shares — an estimated $13.6M sold.

OrbiMed first reported a position in ACIU in Q3 2018 and held it in 2 quarters. The position peaked at $13.6M in Q4 2018. 41 funds tracked by Wall St. Rank hold ACIU as of Q1 2019.

OrbiMed reported no remaining AC Immune position as of Q1 2019 after selling out during the quarter.
OrbiMed sold 1,440,000 AC Immune shares in Q1 2019, an estimated $13.6M.
OrbiMed first reported a position in AC Immune in Q3 2018 and held it in 2 quarters.
OrbiMed's AC Immune position peaked at $13.6M in Q4 2018.
41 funds tracked by Wall St. Rank held AC Immune as of Q1 2019.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.